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Abstract
Background: HIV-1 Tat protein recruits human positive transcription elongation factor P-TEFb,
consisting of CDK9 and cyclin T1, to HIV-1 transactivation response (TAR) RNA. CDK9 is
maintained in dephosphorylated state by TFIIH and undergo phosphorylation upon the dissociation
of TFIIH. Thus, dephosphorylation of CDK9 prior to its association with HIV-1 preinitiation
complex might be important for HIV-1 transcription. Others and we previously showed that
protein phosphatase-2A and protein phosphatase-1 regulates HIV-1 transcription. In the present
study we analyze relative contribution of PP2A and PP1 to dephosphorylation of CDK9 and to HIV-
1 transcription in vitro and in vivo.
Results: In vitro, PP2A but not PP1 dephosphorylated autophosphorylated CDK9 and reduced
complex formation between P-TEFb, Tat and TAR RNA. Inhibition of PP2A by okadaic acid
inhibited basal as well as Tat-induced HIV-1 transcription whereas inhibition of PP1 by recombinant
nuclear inhibitor of PP1 (NIPP1) inhibited only Tat-induced transcription in vitro. In cultured cells,
low concentration of okadaic acid, inhibitory for PP2A, only mildly inhibited Tat-induced HIV-1
transcription. In contrast Tat-mediated HIV-1 transcription was strongly inhibited by expression of
NIPP1. Okadaic acid induced phosphorylation of endogenous as well transiently expressed CDK9,
but this induction was not seen in the cells expressing NIPP1. Also the okadaic acid did not induce
phosphorylation of CDK9 with mutation of Thr 186 or with mutations in Ser-329, Thr-330, Thr-
333, Ser-334, Ser-347, Thr-350, Ser-353, and Thr-354 residues involved in autophosphorylation of
CDK9.
Conclusion:  Our results indicate that although PP2A dephosphorylates autophosphorylated
CDK9 in vitro, in cultured cells PP1 is likely to dephosphorylate CDK9 and contribute to the
regulation of activated HIV-1 transcription.
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Background
Transcription of human immunodeficiency virus (HIV-1)
is activated by viral Tat protein which binds to a transacti-
vation response (TAR) RNA [1-4]. In cell-free transcrip-
tion assays Tat exclusively induces elongation of
transcription [5,6]. In contrast, Tat induces initiation of
transcription from the integrated HIV-1 promoter in the
cells [7-9]. In an early study by Jeang and Berkhout, self-
cleaving ribozymes introduced into TAR RNA inhibited
Tat transactivation when TAR RNA was cleaved quickly,
but not when the cleavage was delayed, indicating that the
initial contact between Tat and TAR RNA rather than
RNAPII pausing was the rate limiting step in Tat transacti-
vation [9]. Recently Green and coworkers showed that Tat
stimulates formation of transcription complex containing
TATA-box-binding protein (TBP) but not TBP-associated
factors (TAFs), thus indicating that Tat may enhance initi-
ation of transcription [7]. This latter finding apparently
agrees with the early observation by Kashanchi and col-
leagues that Tat binds directly to the TBP-containing basal
transcription factor TFIID [10]. Tat activates HIV-1 tran-
scription by recruiting transcriptional co-activators that
include Positive Transcription Elongation Factor b (P-
TEFb), containing CDK9/cyclin T1, an RNA polymerase II
C-terminal domain kinase [6,11,12] and histone acetyl
transferases [13-15]. Whereas P-TEFb induces HIV-1 tran-
scription from non-integrated HIV-1 template [6,11,12],
histone acetyl transferases allow induction of integrated
HIV-1 provirus [13-15]. Cyclin T1 interacts with the loop
of TAR RNA and with Tat through a critically conserved
cysteine; the mutation of which in rodent cells renders Tat
transactivation inefficient [16,17]. In vitro association of
P-TEFb with Tat and TAR RNA is enhanced when CDK9 is
autophosphorylated [18]. We previously showed that in
vitro, unphosphorylated CDK9 associates with the preini-
tiation complex and its phosphorylation is directly inhib-
ited by TFIIH [19]. Upon dissociation of TFIIH during
elongation of transcription, CDK9 undergoes phosphor-
ylation that is induced by Tat [19]. Thus, it appears that
CDK9 might need to be dephosphorylated prior to its
association with the transcription initiation complex. Pre-
viously, two serine-threonine phosphatases, protein
phosphatase 2A (PP2A) and protein phosphates-1 (PP1)
were implicated in the regulation of HIV-1 transcription.
PP2A and PP1 are a general phosphatases that belong to
the PPP-family of protein phosphatases with predomi-
nant nuclear localization [20]. Nuclear PP2A and PP1
consist of a constant catalytic subunit and a variable regu-
latory subunits that determines the localization, activity
and substrate-specificity of the phosphatase [20]. Protein
phosphatase 2A (PP2A) positively regulates HIV-1 tran-
scription as deregulation of cellular enzymatic activity of
PP2A inhibited Tat-induced HIV-1 transcription [21,22].
Expression of the catalytic subunit of PP2A enhanced acti-
vation of HIV-1 promoter by phorbol myristate acetate
(PMA), whereas inhibition of PP2A by okadaic acid and
by fostriecin prevented activation of HIV-1 promoter [22].
One of the major nuclear subunits of PP1 is Nuclear
Inhibitor of PP1 (NIPP1) that binds to the catalytic subu-
nit of PP1 and form an inactive holoenzyme complex
which can be activated by phosphorylation of NIPP1
[23,24]. By using NIPP1 to inhibit nuclear PP1, we have
demonstrated that protein phosphatase-1 (PP1) is a posi-
tive regulator of HIV-1 transcription in vitro [25] and in
vivo [26]. We hypothesized that positive effect on HIV-1
transcription observed by either PP1 or PP2A could be a
result of dephosphorylation of CDK9, which would
increase the amount of active P-TEFb available for recruit-
ment to the HIV-1 promoter. In the present paper we per-
formed a comparative analysis of CDK9
dephosphorylation by PP1 and PP2A in vitro. Autophos-
phorylated CDK9/cyclin T1 was subjected to dephospho-
rylation by PP2A and PP1. Also we analyzed the effect of
dephosphorylation of CDK9 by PP2A or PP1 on the com-
plex formation between Tat, TAR RNA and CDK9/cyclin
T1. Analysis of the effect of PP2A inhibition on HIV-1
transcription in vitro was carried out using okadaic acid,
which inhibits PP2A at low concentration. To inhibit PP1
in HIV-1 transcription in vitro, we used recombinant
NIPP1 protein. In cultured cell, okadaic acid was used to
induce phosphorylation of CDK9, and the cells stably
expressing central domain of NIPP1 were used to deter-
mine whether the okadaic acid induced phosphorylation
was a PP1-dependent effect. Finally, we analyzed phos-
phorylation of CDK9 with mutations in the Thr 186 or
with mutations in Ser-329, Thr-330, Thr-333, Ser-334,
Ser-347, Thr-350, Ser-353, and Thr-354 residues involved
in autophosphorylation of CDK9. Our results indicate
that while PP2A dephosphorylates CDK9 in vitro and it is
PP1 that dephosphorylates CDK9 in vivo, and thus might
have a regulatory role in HIV-1 transcription.
Results
PP2A dephosphorylates CDK9 in vitro
We explored whether PP2A or PP1 dephosphorylates
CDK9 in vitro. CDK9 within the recombinant CDK9/cyc-
lin T1 was autophosphorylated in the presence of γ-(P32)-
ATP. The kinase activity of CDK9 was blocked by the addi-
tion of 7 mM EDTA and (32P) phosphorylated CDK9 was
used as a substrate for PP1 or PP2A (Fig. 1A, lane 1).
While PP2A efficiently dephosphorylated CDK9 (Fig. 1A,
lanes 4 and 5), PP1 was approximately 10-time less effi-
cient than PP2A in the dephosphorylation (Fig. 1A, lanes
2 and 3). Based on their activities towards the reference
substrate, glycogen phosphorylase-a [27], PP1 was added
at 1.5-fold higher activity than PP2A (Fig. 1B) and thus
PP1 was even less efficient than PP2A, at least 20-time less
efficient in dephosphorylation of CDK9.Retrovirology 2005, 2:47 http://www.retrovirology.com/content/2/1/47
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PP2A dephosphorylates CDK9 in vitro Figure 1
PP2A dephosphorylates CDK9 in vitro. A, Dephosphorylation of CDK9 by PP2A and PP1. Recombinant CDK9/cyclin T1 
was incubated with γ-(32P) ATP to allow autophosphorylation (lane 1). The kinase activity was blocked by 7 mM EDTA and 
CDK9 was used as a substrate for PP1 (lanes 2 and 3) or PP2A (lanes 4 and 5). Dephosphorylated CDK9 was resolved on 10% 
SDS-PAGE and quantified on PhosphoImager (lower panel). B, Phosphorylase-a phosphatase activity of PP1 and PP2A at con-
centrations corresponding to panel A, presented as the amount of phosphorylase-a remained in the reaction after the treat-
ment with the phosphatase. C, Pre-treatment with PP2A increases autophosphorylation of CDK9. Recombinant CDK9/cyclin 
T1 was incubated without (lane 1) or with PP1 (lanes 2 and 3) or PP2A (lanes 4 and 5) at concentrations corresponding to 
Panel A. After incubation, the phosphatases were blocked with 1 µM okadaic acid and CDK9/cyclin T1 was subjected to the 
autophosphorylation with γ-(32P) ATP (lanes 1 to 5). Phosphorylated CDK9 was resolved on 10% SDS-PAGE and exposed to 
the PhosphoImager screen.
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Dephosphorylation by PP2A enhances CDK9 
autophosphorylation in vitro
Recently, CDK9 within the recombinant P-TEFb purified
from insect cells was found to be phosphorylated on T186
[28]. We explore here whether CDK9 might be already in
the phosphorylated state in our preparation of the recom-
binant P-TEFb. We asked whether dephosphorylation by
either PP2A or PP1 of CDK9/cyclin T1 would enhance
phosphorylation of CDK9 in the following kinase reac-
tion. Recombinant CDK9/cyclin T1 was incubated with
increasing concentrations of PP1 or PP2A followed by
inhibition of the phosphatases with 1 µM okadaic acid.
Then the autophosphorylation reaction was carried out in
the presence of γ-(32P)-ATP (Fig. 1C). Treatment with
PP2A (Fig. 1C, lanes 4 and 5) but not with PP1 (Fig. 2,
lanes 2 and 3) increased the efficiency of CDK9 autophos-
phorylation. This result indicates that recombinant CDK9
was already in partially phosphorylated state and that
PP2A-mediated dephosphorylation of CDK9 enhanced
subsequent phosphorylation of CDK9.
Dephosphorylation of CDK9 by PP2A prevents formation 
of P-TEFb/Tat/TAR RNA complex in vitro
We next analyzed whether dephosphorylation of CDK9
by PP2A or by PP1 has an effect on formation of a com-
plex between recombinant P-TEFb, HIV-1 Tat and TAR
RNA. We utilized a biotinylated TAR RNA that was prein-
cubated with recombinant Tat and recombinant CDK9/
cyclin T1 and then precipitated with streptavidin agarose
beads (Figs. 2A and 2B, lane 3). When TAR RNA was dena-
tured or when Tat was omitted, CDK9/cyclin T1 was not
precipitated with TAR RNA (Figs. 2A and 2B, lanes 1 and
2) indicating a specific P-TEFb:Tat:TAR RNA complex for-
mation. Pre-treatment of CDK9/cyclin T1 with PP2A
resulted in a significant decrease in the complex forma-
tion (Fig. 2A, lane 4). In contrast, pretreatment of CDK9/
cyclin T1 with PP1 did not have an effect on P-TEFb: Tat:
TAR RNA complex formation (Fig. 2B, lane 4). These
results indicate that PP2A but not PP1 affects formation of
the P-TEFb: Tat: TAR RNA complex in vitro.
Inhibition of PP2A by okadaic acid blocks basal and Tat-
dependent HIV-1 transcription in vitro
Next we analyzed whether inhibition of PP2A has an
effect on HIV-1 transcription in vitro. An HIV-1 LTR tem-
plate that contains 308 nucleotides downstream of the
transcription start was prepared by PCR using HIV-1 LTR-
LacZ expression vector (see Methods). Purified Tat stimu-
lated transcription on this template in the HeLa nuclear
extract to approximately 5-fold (Fig. 3A). We used okadaic
acid, which is a 100-fold more efficient in vitro inhibitor
of PP2A than PP1 (Fig. 3B) to determine the effect of PP2A
inhibition on HIV-1 transcription. Two different concen-
trations of okadaic acid were used: 10 nM – to inhibit
PP2A and 1 µM – to inhibit PP1. Addition of either 10 nM
or 1 µM concentrations of okadaic acid inhibited basal
HIV-1 transcription (Fig. 3C, compare lanes 4 and 5 to
lane 2) and also Tat-activated HIV-1 transcription (Fig.
3C, compare lanes 6 and 7 to lane 3). Thus this result indi-
cates that inhibition of PP2A blocks both basal and Tat-
activated transcription.
Inhibition of PP1 by NIPP1 blocks Tat-dependent HIV-1 
transcription in vitro
we cannot rule out the possibility that PP1 might also be
involved in the HIV-1 transcription in vitro. We used
recombinant NIPP1 protein which we previously used to
inhibit PP1 in vitro [29]. Similar to the experiment in the
previous section, purified Tat stimulated transcription
about 4-fold (Fig. 3D, compare lanes 2 and 3). Addition
of NIPP1 inhibited Tat-activated transcription (Fig. 3D,
lane 5), but did not affect basal HIV-1 transcription (Fig.
3D, lanes 4). This result indicates that PP1 might be
involved in the Tat-activated transcription.
Inhibition of PP1 but not PP2A significantly inhibits Tat-
dependent HIV-1 transcription in cultured cells
We next determined relative contribution of PP1 and
PP2A to basal and Tat-activated HIV-1 transcription in
cultured COS-7 cells using selective inhibition of PP2A
and PP1. We used okadaic acid which selectively inhibits
PP2A in vitro at concentrations below 1 nM (Fig. 3B) but
which would inhibit both PP1 and PP2A at higher con-
centrations. COS-7 cells were co-transfected with Tat-
expressing vector and HIV-1 LTR-LacZ (JK2) and expres-
sion of β-galactosidase was analyzed using quantitative
ONPG-based assay [26]. In these cells Tat potently stimu-
late transcription from HIV-1 LTR (Fig. 4A, compare lanes
1 and 2). Treatment of the transfected COS-7 cells with
okadaic acid resulted in partial (about 30%) inhibition of
Tat-induced transcription (Fig. 4A). The IC50 of the oka-
daic acid-mediated inhibition was 4 nM (Fig. 4B). Surpris-
ingly, okadaic acid had no inhibitory effect on HIV-1
basal transcription from a mutant HIV-1 LTR with a dele-
tion of the fragment encoding TAR RNA (HIV-1 LTR∆
TAR) (Fig. 4C). At the concentrations below 10 nM,
treatment with okadaic acid did not affect viability of
COS-7 cells (see supplemental Fig). These results indicate
that PP2A has a moderate effect only on Tat-induced tran-
scription in cultured cells. To analyze the contribution of
PP1 to the control of HIV-1 transcription in COS-7 cells,
vectors expressing NIPP1-EGFP WT or NIPP1-EGFP
mutant (NIPP1 K193-197A/V201A/F203A/Y335D,
NIPP1 mut) were transfected along with JK2 and Tat
expression vector, as we previously described [26]. In the
mutant NIPP1 the PP1 binding sites in both the central
and C-terminal domain of NIPP1 are mutated and it no
longer interacts with PP1 [30]. Co-transfection of wild
type, but not the mutant NIPP1-EGFP, inhibited Tat-acti-
vated transcription (Fig. 5A, lanes 3 and 4). In the absenceRetrovirology 2005, 2:47 http://www.retrovirology.com/content/2/1/47
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Binding of Tat to TAR RNA and CDK9/cyclin T1 Figure 2
Binding of Tat to TAR RNA and CDK9/cyclin T1. Precipitation of biotin TAR RNA with purified Tat and with CDK9/
cyclin T1. Lane 1, control denatured TAR RNA. Lane, control without Tat. Lane 3, untreated CDK9. cyclin T1. Lane 4, CDK9/
cyclin T1 treated with PP2A (panel A) or with PP1 (panel B). Precipitated proteins and TAR RNA were recovered in SDS-load-
ing buffer, resolved 12% SDS-PAGE and immunoblotted with indicated antibodies. Position of TAR RNA was determined by 
Ponceau-S staining.
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Contribution of PP2A and PP1 to Tat-activated transcription in vitro Figure 3
Contribution of PP2A and PP1 to Tat-activated transcription in vitro. A, In vitro transcription reactions were carried 
with the indicated amounts of recombinant Tat. Lane 1, no DNA template; lane 2, no Tat added; lanes 3–5, Tat added at 10 ng, 
50 ng and 100 ng correspondingly. Transcription product was resolved on 5 % Urea-PAGE, exposed to the PhosphoImager 
screen and quantified. B, Inhibition of PP1 and PP2A by okadaic acid in phosphorylase-a dephosphorylation assay. PP1 and 
PP2A were inhibited by okadaic acid with IC50 = 70 nM and 0.4 nM concentration of inhibitor respectively. C, Okadaic acid 
inhibits basal and Tat-activated transcription. Lane 1, no DNA template; lane 2, no Tat added; lane 3, transcription with 50 ng 
of Tat; lanes 4 and 5, transcription in the absence of Tat and with 10 nM or 1 µM of okadaic acid; and lanes 6 and 7, transcrip-
tion in the presence of 50 ng of Tat and with 10 nM or 1 µM of okadaic acid. Transcription products were resolved on 5 % 
Urea-PAGE, exposed to the PhosphoImager screen and quantified. D, NIPP1 inhibits Tat-activated transcription. Lane 1, no 
DNA template; lane 2, no Tat added; lane 3, transcription with 50 ng of Tat; lane 4, transcription in the absence of Tat and with 
100 ng NIPP1; lane 5, transcription in the presence of 50 ng of Tat and 100 ng NIPP1. Transcription products were resolved on 
5 % Urea-PAGE, exposed to the PhosphoImager screen and quantified.
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Okadaic acid modestly inhibits Tat-induced HIV-1 transcription in cultured cells Figure 4
Okadaic acid modestly inhibits Tat-induced HIV-1 transcription in cultured cells. A, COS-7 cells were co-trans-
fected without (lane 1) or with Tat-expressing vector and HIV-1 LTR-LacZ (lanes 2–10). Cells were also treated with indicated 
concentrations of okadaic acid (lanes 3–10). Expression of β-galactosidase was analyzed using ONPG-based assay. B, Quantifi-
cation of the inhibition of Tat-induced transcription by okadaic acid using Prism. C, COS-7 cells were transfected with mutant 
HIV-1 LTR with a deletion of the fragment encoding TAR RNA (HIV-1 LTR∆TAR) without (lanes 1 and 3–10) or with Tat-
expression plasmid (lane 2) and treated with the indicated concentrations of okadaic acid (lanes 3–10).
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Expression of NIPP1 inhibits Tat-dependent HIV-1 transcription in COS-7 cells Figure 5
Expression of NIPP1 inhibits Tat-dependent HIV-1 transcription in COS-7 cells. A, Lane 1, COS-7 cells grown in 
24-well plate were transfected with the indicated amount of JK2 using Ca2+-phosphatase method. Lane 2, COS-7 cells were 
transfected with 25 ng of JK2 and indicated amount of Tat expression plasmid. Lane 3 and 4, COS-7 cells were transfected with 
25 ng of JK2, 50 ng of Tat expression vector and indicated amounts of wild type or mutant NIPP1. B, NIPP1 and mutant NIPP1 
equally affect HIV-1 transcription in the absence of Tat. COS-7 cells were transfected with 50 ng of JK2 or JK2∆TAR and with 
indicated amounts of NIPP1 or mutant NIPP1.
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of Tat, transcription from HIV-1 LTR or from a mutant
HIV-1 LTR with a deletion of the fragment encoding TAR
RNA (JK2∆TAR) was inhibited about 50% by both NIPP1
and mutant NIPP1 (Fig. 5B), indicating that this effect of
NIPP1 was not due to its ability to bind PP1. Taken
together, inhibition of PP1 by over expression of NIPP1
reduces Tat-dependent HIV-1 transcription by 70%, in
accord to our previous study [26], Thus PP1 and less likely
PP2A might contribute to the regulation of Tat-dependent
HIV-1 transcription.
CDK9 is dephosphorylated by PP1 in cultured cell
We next analyzed whether CDK9 phosphorylation state is
controlled by PP1 or by PP2A in cultured cells. HeLa cells
were labelled with (32P) orthophosphate in the absence
and in the presence of okadaic acid and cellular extracts
were immunoprecipitated with anti-cyclin T1 antibodies,
resolved by 10% SDS-PAGE and transferred to PVDF
membrane. Position of CDK9 was determined by probing
the membrane with anti-CDK9 antibodies using 3,3'-
Diaminobenzidine enhancer system (Fig. 6A). Precipita-
tion of CDK9 from untreated cells and from the cells
treated with okadaic acid showed that phosphorylation of
CDK9 was increased in the presence of okadaic acid (Fig.
6B, lanes 1 and 2). To analyze whether this increase was
due to inhibition of PP1 or PP2A, we utilized 293T cells
that were stably transfected with the central domain of
NIPP1 (residues 143–224) (293T-cdNIPP1 cells), an
equally potent inhibitor of PP1 as full length NIPP1 [30].
Precipitation of endogenous CDK9 from untreated 293T-
cdNIPP1 cells labeled with (32P) in the absence or in the
presence of 100 nM okadaic acid showed equal low level
of CDK9 phosphorylation (Fig. 6C, lanes 1 and 2). To fur-
ther investigate whether CDK9 phosphorylation was
caused by PP1, we transiently express Flag- tagged CDK9
in 293T-cdNIPP1 cells, labeled cells with (32P) and precip-
itated CDK9 with anti-Flag antibodies. Again treatment
with 100 nM okadaic acid did not increase phosphoryla-
tion of CDK9 (Fig. 6D, lanes 1 and 2). Taken together
these results indicate that CDK9 is dephosphorylated in
vivo and that it is likely PP1 that dephosphorylates CDK9.
To further explore the CDK9 dephosphorylation, we ana-
lyzed phosphorylation of CDK9 mutants with mutation
in Thr 186 (T186A mutant) or with mutations in Ser-329,
Thr-330, Thr-333, Ser-334, Ser-347, Thr-350, Ser-353, and
Thr-354 residues (C8A mutant). 293T cells were
transiently transfected with Flag-tagged CDK9, WT, T186A
mutant or C8A mutant. Transfected cells were labeled
with (32P) without or with the addition of 100 nM oka-
daic acid. Precipitation of CDK9 with anti-Flag antibodies
showed that while okadaic acid induced phosphorylation
of WT CDK9 (Fig. 7A, lanes 2 and 3; and Fig. 7B), there
was no further increase in phosphorylation of T186A or
C8A mutant (Fig. 7A, lanes 4 to 7: and Fig. 7B). Interest-
ingly, mutation of Thr 186 increases CDK9 phosphoryla-
tion level (Fig. 7A, lane 5 and Fig. 7B).
Taken together our results indicate that PP1 may poten-
tially dephosphorylate Thr 186 as well as the C-terminal
serines involved in the autophosphorylation of CDK9 and
that dephosphorylation of CDK9 may have a regulatory
effect in Tat-activated HIV-1 transcription.
Discussion
In this study, we show that while PP2A dephosphorylates
CDK9 in vitro, in cultured cells PP1 preferentially dephos-
phorylates CDK9 and largely contributes to the regulation
of activated HIV-1 transcription. Previously PP2A has
been shown to stimulate HIV-1 transcription [22].
Because PP2A exists in multiply complexes it is still not
clear what is the substrate for PP2A during HIV-1 tran-
scription. Results presented in the present paper show that
it is unlikely that PP2A dephosphorylates CDK9 in vivo.
Previously, CDK9 phosphorylation was linked to the
binding of CDK9/cyclin T1 to TAR RNA in the presence of
Tat [18]. Our in vitro data are clearly in agreement with the
earlier observations. Recently, acetylation of the RNA
binding region of Tat was shown to be important for Tat
function in vivo and it was proposed to help in dissociat-
ing CyclinT1 from TAR RNA [31]. Thus it is remained to
be determined whether autophosphorylation of CDK9 is
important for P-TEFb interaction with TAR RNA in vivo
and whetherphosphorylation of the C-terminus of CDK9
is linked to the acetylation of Tat. In our study, PP2A
affected both basal and Tat-induced HIV-1 transcription.
This indicates that PP2A may be important for the early
steps of transcription. Since β-galactosidase is quite stable,
our experimental system allows us to measure only gen-
eral cumulative effects and thus we may have overlooked
the early transcriptional effects. The inhibitory effect of
NIPP1 on Tat-dependent transcription in vitro agrees well
with our previous observation that inhibition of PP1
blocks Tat-activated but not basal HIV-1 transcription
[26]. But generally the effect of Tat in vitro in our system
was relatively small, only 3–5 folds induction, as com-
pared to the 30-fold or more induction in the cells. Thus
it is possible that either the basal transcription in vitro was
artificially high, or that the Tat activation only partially
reproduces the situation in vivo. Our unpublished obser-
vations indicate that Tat may directly interact with PP1 in
vivo and retarget PP1 within the cells, the effect that may
not be seen in vitro. We chose for the analysis COS-7 cells
in which HIV-1 transcription is not induced in response to
the low concentration of the okadaic acid, likely because
of the retargeting of PP2A by SV40 small T antigen [32].
We showed that low concentrations of okadaic acid (IC50
= 4 nM) mildly inhibit Tat-induced but not the basal HIV-
1 transcription. The level of the achieved inhibition was
only 30% indicating that phosphatases, including PP1Retrovirology 2005, 2:47 http://www.retrovirology.com/content/2/1/47
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may also contribute to the regulation of HIV-1 transcrip-
tion. Our previous study [26] and the results presented
here indicate that PP1 may be one of the candidate phos-
phate, as inhibition of nuclear PP1 potently blocked Tat-
transactivation. Analysis of the CDK9 phosphorylation in
cultured cells showed that its phosphorylation is likely to
be controlled by PP1 because in the cells, that stably
express central domain of NIPP1, there was no increase of
CDK9 phosphorylation in the presence of okadaic acid. A
more complex explanation is that PP1 might regulate
PP2A activity and thus indirectly affect CDK9 phosphor-
ylation. Although the moderate inhibitory effect of oka-
CDK9 is dephosphorylated by PP1 in cultured cells Figure 6
CDK9 is dephosphorylated by PP1 in cultured cells. A, Immunoprecipitation of CDK9. Lane 1, CDK9 was precipitated 
from HeLa cell extract with anti-cyclin T1 antibodies, resolved on 10% SDS-PAGE and immunoblotted with anti-CDK9 anti-
bodies; Lane 2, immunoprecipitation of recombinant CDK9/cyclin T1; Lanes 3, input recombinant CDK9/cyclin T1; lane 4, 
input HeLa cell extract. B, HeLa cells were labelled with (32P) orthophosphate in the absence (lane 1) and in the presence of 1 
µM okadaic acid (lane 2) and cellular extracts were immunoprecipitated with anti-cyclin T1 antibodies, resolved by 10% SDS-
PAGE and transferred to PVDF membrane. Position of CDK9 was determined by probing the membrane with anti-CDK9 anti-
bodies using 3,3'-Diaminobenzidine enhancer system. The picture is autoradiogram of the membrane exposed to phosphor 
imager screen. C, 293T cells were labeled with (32P) orthophosphate in the absence (lane 1) and in the presence of 100 nM 
okadaic acid (lane 2) and cellular extracts were immunoprecipitated with anti-CDK9 antibodies, resolved by 10% SDS-PAGE 
and transferred to PVDF membrane. Position of CDK9 was determined by probing the membrane with anti-CDK9 antibodies 
using 3,3'-Diaminobenzidine enhancer system. The picture is an autoradiogram of the membrane exposed to phosphor imager 
screen. D, 293T-cdNIPP1 cells stably expressing central domain of NIPP1 (143–224) were transfected with Flag-CDK9 expres-
sion vector and labeled with (32P) orthophosphate in the absence (lane 1) and in the presence of 100 nM okadaic acid (lane 2). 
Cellular extracts were immunoprecipitated with anti-Flag antibodies, resolved by 10% SDS-PAGE and transferred to PVDF 
membrane. Position of CDK9 was determined by probing the membrane with anti-CDK9 antibodies using 3,3'-Diaminobenzi-
dine enhancer system. The picture is autoradiogram of the membrane exposed to phosphor imager screen.
1   2  3 4
A
IP Input
CDK9
OA - +
CDK9
B
1  2 
a-CDK9
Rec P-TEFb - + - +
HeLa Cells    +  - + -
C
(32P) CDK9
OA - +
(32P)
12
D
OA - +
(32P)
α-Flag
CDK9
CDK9Retrovirology 2005, 2:47 http://www.retrovirology.com/content/2/1/47
Page 11 of 15
(page number not for citation purposes)
daic acid on HIV-1 transcription argues against this
possibility, we cannot exclude it completely. CDK9/cyclin
T1 was shown to bind to its inhibitors, 7SK RNA and
MAQ1/HEXIM1 protein in phosphorylation-dependent
manner [33]. Autophosphorylation of CDK9 takes place
in the C-terminus [18], whereas a yet unknown cellular
kinase phosphorylates CDK9 within the regulatory T-loop
[33]. It was proposed that phosphorylation of Thr 186
inhibits the activity of P-TEFb and that its dephosphoryla-
tion reactivates P-TEFb by allowing dissociation of 7SK
RNA and HEXIM1 [33]. In a contradictory study, Price and
colleagues showed that phosphorylation of Thr 186 is
Determination of CDK9 residues dephosphorylated in cultured cells Figure 7
Determination of CDK9 residues dephosphorylated in cultured cells. A, 293T cells were transfected with expression 
vectors Flag-tagged CDK9 (lanes 2 and 3), CDK9 T186A mutant (lanes 4 and 5) and CDK9 C8A mutant (lanes 6 and 7). Cells 
were labeled with (32P) orthophosphate in the absence (lanes 2, 4 and 6) and in the presence of 100 nM okadaic acid (lane 3, 5 
and 7). Lane 1, mock transfected cells. Cellular extracts were immunoprecipitated with anti-Flag antibodies, resolved by 10% 
SDS-PAGE and transferred to PVDF membrane. Upper panel shows expression of CDK9 determined by probing the mem-
brane with anti-CDK9 antibodies using 3,3'-Diaminobenzidine enhancer system. Lower panel is an autoradiogram of the mem-
brane exposed to phosphor imager screen. B, quantification of the Phosphor Imager panel.
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required for the kinase activity of CDK9 and argued
against the regulatory role of dephosphorylation of
Thr186 [28]. Our study points to a possibility to resolve
this discrepancy by determining the phosphorylation
state of Thr 186 and the activity of endogenous CDK9 in
the cells which continuously express central domain of
NIPP1. Taking together, our study demonstrates that PP1
is likely to dephosphorylate CDK9 in vivo and that inhib-
itory effect of NIPP1 on HIV-1 transcription might be due
to the deregulation of CDK9 phosphorylation.
Methods
Materials
COS-7 cells, 293T cells and HeLa cells were purchased
from ATCC (Manassas, VA). 293T cells stably expressing
NIPP1 (143–224) were generated by transfection of
NIPP1-143-224-EGFP, and limited dilution cloning in the
presence of geneticin (0.5 mg/ml) (Life Technologies,
Rockville, MD). Human protein phosphatase PP2A was
purchased from Upstate Biotechnology (Lake Placid, NY).
Rabbit protein phosphatase PP1 and recombinant NIPP1
were gifts from M. Bollen (Catholic University, Leuven,
Belgium). Phosphorylase b was from Calzyme Laborato-
ries (San Luis Obispo, CA). Protein (A) agarose was pur-
chased from Sigma (Atlanta, GA). Human recombinant P-
TEFb from baculovirus transfected Sf9 cells (NCCC) was
purified as described in [34].
Antibodies
Rabbit polyclonal antibodies to CDK9 and goat polyclo-
nal antibodies to cyclin T1 were purchased from Santa
Cruz Biochemical (Santa Cruz, CA).
Plasmids
The reporter plasmid, pJK2, contained HIV-1 LTR (-138 to
+82) followed by nuclear localization signal (NLS) and
lacZ  reporter gene (courtesy of Dr. Michael Emerman,
Fred Hutchinson Cancer Institute, Seattle, WA). This plas-
mid expresses NLS-tagged β-galactosidase under the con-
trol of HIV-1 LTR [35]. Tat expression plasmid was a gift
from Dr. Ben Berkhout (University of Amsterdam) [36].
The pGEM2Tat bacterial expression vector was obtained
from NIH AIDS Research and Reference Reagents
Program.
CDK9 autophosphorylation and dephosphorylation in 
vitro
Recombinant CDK9/cyclin T1 (30 ng/reaction) was auto-
phosphorylated in 20 µl reaction with 50 µM ATP (1 µCi
of γ-(32P)ATP) in kinase buffer (50 mM HEPES (pH 7.9),
10 mM MgCl2, 6 mM EGTA and 2.5 mM DTT) for 1 hour
at 30°C. The reaction was supplemented with 7 mM
EDTA to inactivate the kinase, followed by addition of
PP2A or PP1 and incubation for 30 min at 30°C. Dephos-
phorylation of recombinant CDK9/cyclin T1 was carried
out in Tris-HCl buffer pH 8.0, 5 mM MgCl2, 5 mM MnCl2,
20 µM ZnSO4 using indicated amount of PP1 or PP2A.
The phosphatases were inhibited with 1 µM okadaic acid.
The 250 nM ATP and 5 µCi γ-(32P)ATP were added in the
same buffer and incubated for 30 min at 30°C. Reactions
were resolved on 10% SDS-PAGE and subjected to autora-
diography and quantification with PhosphorImager
Storm 860 (Molecular Dynamics).
Preparation of phosphorylase-a and dephosphorylation 
assay
10 mg of phosphorylase-b was dissolved in 300 µl BFA
(10 mM glycerophosphate pH 7.4, 50 mM 2-mercap-
toethanol) and dialyzed against the same buffer for 2 to 3
hours. Then 7.5 µl 500 mM Tris-HCl (pH 8.0) and 6 µl
phosphorylase kinase were added and incubated 10 min
30°C followed by addition of 45 µl ATP-Mg mix (8.3 mM
ATP, 83 mM MgCl2, 75 µCi γ-(32P)ATP) and incubation
for 2 h at 30°C. Phosphorylase-a was precipitated with
ammonium sulfate, resuspended in BFA and dialyzed
against BFA for 1 to 2 day at 4°C. AG 501 × 8 (mixed
anion and cation exchange) resin was placed in a separate
dialysis bag to improve removal of unincorporated ATP
and inorganic phosphate. Dialyzed phosphorylase-a was
kept at 4°C. Approximately 0.2 nmol of phosphorylase-a
was used as a substrate for PP1 or PP2A. The phosphory-
lase phosphatase assay was carried out for 10 min in a
buffer containing 50 mM glycylglycine at pH 7.4, 0.5 mM
dithiothreitol, and 5 mM β-mercaptoethanol as described
[27].
In vitro interaction of biotinylated TAR RNA, Tat and 
CDK9/cyclin T1
Biotin-TAR RNA (51 nucleotides) was purchased from
Molecula company http://www.molecula.com. To bind
TAR RNA, streptavidin-agarose beads were washed with
binding buffer (20 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2,
100 mM NaCl) and incubated with TAR RNA (5 µg/reac-
tion) or formamide denatured TAR RNA for 30 min at
4°C. The beads were washed with the binding buffer and
incubated with recombinant Tat protein (1.5 µg/reaction)
for 30 min at 4°C. Beads were washed with binding buffer
and then with TAK buffer (50 mM Tris-HCl, pH 8.0, 5 mM
MgCl2, 5 mM MnCl2, 10 µM ZnSO4, 1 mM DTT) contain-
ing 100 mM NaCl. Then 64 µg of yeast tRNA and 100 µg
of BSA were added per reaction to block the beads. Then
recombinant CDK9/cyclin T1 (30 ng/reaction) was added
in TAK buffer containing 100 mM NaCl. Protein phos-
phatases PP1 and PP2A were diluted in TAK buffer and
added into reaction where indicated at 0.1U of PP1 or
0.04U of PP2A. Samples were incubated for 1 h on ice
with occasional mixing. Then beads were washed 3 times
with the binding buffer, and bound proteins and RNA
were eluted in 1× SDS-loading buffer. Proteins were sepa-
rated on 12% SDS-PAGE, transfer to PVDF membrane,Retrovirology 2005, 2:47 http://www.retrovirology.com/content/2/1/47
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immunoblotted with α-CDK9 (Santa Cruz Biotechnol-
ogy) and α-Tat 4A4.8 (NIH, AIDS Research Program)
antibodies. Biotin TAR RNA was detected by Ponceau S
staining.
In vitro transcription assay
Biotinylated HIV-1 LTR DNA template which included-
111 to +308 nucleotides of JK2 (HIV-1 LTR nucleotides-
111 to +82) was amplified by PCR with the forward
primer 5' biotinylated-TTCTACAAGGGACTTTCCGC-3'
and the reverse primer 5'-CAGTACAGGCAAAAAGCAGC-
3' (Life Technologies, Rockville, MD). Transcription reac-
tions (20 µl) contained 75 µg of HeLa nuclear extract, 0.5
mM of each ATP, CTP and GTP, 20 µM UTP, 2 µCi
[α32P]UTP, 0.2–0.4 µg of the template in transcription
buffer (20 mM HEPES at pH 7.9, 50 mM KCl, 6.25 mM
MgCl2, 0.5 mM EDTA, 2 mM DTT and 10% glycerol),
RNAsin and a recombinant pGEM2 Tat72 for transactiva-
tion reaction. 10 nM okadaic acid has been used for
inhibition of serine/threonine phosphatases. After 30 min
incubation at 30°C, reactions were treated with protein-
ase K for 15 min at 55°C, and extracted with phenol-chlo-
roform-isoamylalcohol(LifeTechnologies, Rockville,
MD). RNA was precipitated from the water phase and
resolved on 5% sequencing polyacrylamide gels contain-
ing 7 M urea. Mcp 1 digested PBR 322 plasmid (LifeTech-
nologies, Rockville, MD) labeled with Klenow fragment
and 32P-labeled dCTD served as molecular weight mark-
ers. The labeling was quantified by phosphor imaging
(Packard Instruments).
Transient transfections
COS-7 cells were cultured at 7 × 105 cells/well in DMEM
containing 10% fetal bovine serum. Co-transfections with
Tat-expressing vector and HIV-1 LTR-LacZ or HIV-1 LTR∆
TAR were performed at 75% confluency using a Ca2+ –
phosphate protocol and the indicated reporter plasmids.
After transfection the cells were cultured for an additional
48 hours and β-galactosidase activity was analyzed using
quantitative ONPG-based assay [26]. Where indicated,
okadaic acid was added to transfected cells. Transfections
were normalized using MTT assay (Sigma).
β-galactosidase assays
Cells were washed with phosphate-buffered saline (PBS)
and lysed for 20 min at room temperature in 50 µl of lysis
buffer, containing 20 mM HEPES at pH 7.9, 0.1% NP-40
and 5 mM EDTA. Subsequently, 100 µl of o-nitrophenyl-
β-D-galactopyranoside (ONPG) solution (72 mM Na2
PO4 at pH 7.5, 1 mg/ml ONPG, 12 mM MgCl2, 180 mM
2-mercaptoethanol) was added and incubated at room
temperature until a yellow color was developed. The reac-
tion was stopped by addition of 100 µl of 1 M Na2CO3.
The 96-well plate was analyzed in a micro plate reader at
414 nm (Lab Systems Multiscan MS).
In vivo labeling with (32P) orthophosphate and Western 
blot
HeLa or 293T cells were incubated with phosphate-free
DMEM media (Life Technologies, Rockville, MD) con-
taining no serum for 1 hour. The media was changed to
phosphate-free DMEM media supplemented with 0.5
mCi/ml of (32P)-orthophosphate and cells were further
incubated for 2 hours at 37°C. Where indicated, 0.1 µM
okadaic acid (Sigma) was added to block cellular PPP-
phosphatases. Cells were washed with PBS and lyzed in a
buffer containing 50 mM Tris-HCl, pH 7.5, 0.5 M NaCl,
1% NP-40, 0.1% SDS and protease cocktail (Sigma). After
10 min on ice, cellular material was scraped and then cen-
trifuged at 14,000 rpm, 4°C for 30 min. The supernatant
was recovered and used for immunoprecipitation. CDK9
was co-precipitated with anti-cyclin T1 antibodies cou-
pled to protein A agarose for 2 h at 4°C in a TNN Buffer
containing 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, and
1% NP-40. The immunoprecipitated P-TEFb was recov-
ered by heating for 2 min at 100°C in Tris-SDS loading
buffer, resolved on 10% SDS-PAGE (25) and transferred
to polyvinylidene fluoride (PVDF) membranes (Milli-
pore, Allen, TX). The membrane was analyzed with anti-
CDK9 polyclonal antibodies using 3,3'-Diaminobenzi-
dine enhancer system (Sigma) and was also exposed to
Phosphor Imager screen (Packard Instruments, Wellesley,
MA).
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